| Literature DB >> 32477079 |
Lenette M Jones1, Emily Ginier2, Joseph Debbs1, Jarrod L Eaton1, Catherine Renner1, Jaclynn Hawkins3, Rosanna Rios-Spicer1, Emily Tang1, Catherine Schertzing1, Bruno Giordani4.
Abstract
Introduction/Purpose: Cardiovascular disease (CVD) is the leading cause of death worldwide, and in the United States alone, CVD causes nearly 840,000 deaths annually. Using functional magnetic resonance imaging (fMRI), a tool to assess brain activity, researchers have identified some brain-behavior connections and predicted several self-management behaviors. The purpose of this study was to examine the sample characteristics of individuals with CVD who participated in fMRI studies.Entities:
Keywords: cardiovascular disease; chronic illness; fMRI; health disparities; sample demographics
Year: 2020 PMID: 32477079 PMCID: PMC7240043 DOI: 10.3389/fnhum.2020.00108
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Figure 1Study eligibility flow diagram.
Geographic location.
| Stroke | USA | 15 |
| Germany | 4 | |
| Korea | 3 | |
| United Kingdom | 3 | |
| Austria | 2 | |
| Canada | 2 | |
| Czech Republic | 2 | |
| Brazil | 1 | |
| China | 1 | |
| Finland | 1 | |
| France | 1 | |
| Italy | 1 | |
| Japan | 1 | |
| Netherlands | 1 | |
| CKD/ESRD | China | 2 |
| Germany | 1 | |
| USA | 2 | |
| Type 2 DM | China | 1 |
| HTN | USA | 1 |
CKD, chronic kidney disease; ESRD, end-stage renal disease; DM, diabetes mellitus; HTN, hypertension.
Summary of studies.
| Stroke | 38 | 32 RCTs | 6 cohort | Lowest mean age reported: 40 (range = 34,67) | Highest mean age reported: 73 (SD = 4) | Males > females | •Areas of chronic diaschisis or peristroke areas |
| CKD/ESRD | 4 | 4 cohort | Lowest mean age reported: 34 (SD = 7) | Highest mean age reported: 72 (SD = 7) | Males > females | •Default mode network | |
| Type 2 diabetes | 1 | Cohort | 41 (range = 31, 53) | Males > females | •Anterior cingulate cortex | ||
| Hypertension | 1 | Cohort | 67 (SD = 8.9) | Males < females | •Frontal and medial | ||
CKD, chronic kidney disease; ESRD, end-stage renal disease; RCT, randomized controlled trial.
Study characteristics.
| Brownsett et al. ( | Stroke | 16 | – | + | + | – | + |
| Carey et al. ( | Stroke | 10 | – | + | + | – | – |
| Deng et al. ( | Stroke | 16 | – | + | + | – | – |
| Fair et al. ( | Stroke | 6 | – | – | – | – | – |
| Gold et al. ( | Hypertension | 54 | – | + | – | – | – |
| He et al. ( | Type 2 diabetes | 24 | – | + | + | – | + |
| Hodgson et al. ( | Stroke | 16 | – | + | + | – | + |
| Jahanian et al. ( | CKD | 20 | – | + | + | – | – |
| Kato et al. ( | Stroke | 11 | – | + | + | – | – |
| Kielar et al. ( | Stroke | 38 | – | + | + | – | + |
| Kim et al. ( | Stroke | 18 | – | + | + | – | – |
| Kimberley et al. ( | Stroke | 16 | – | + | + | – | – |
| Kononen et al. ( | Stroke | 11 | – | + | + | – | – |
| Kwon et al. ( | Stroke | 31 | – | + | + | – | – |
| Landsmann et al. ( | Stroke | 24 | – | + | + | – | + |
| Lazaridou et al. ( | Stroke | 17 | – | – | – | – | – |
| Li et al. ( | ESRD | 51 | – | + | + | – | + |
| Luft et al. ( | Stroke | 71 | + | + | + | – | – |
| Luft et al. ( | Stroke | 21 | – | + | + | – | – |
| Luft et al. ( | Stroke | 28 | – | + | + | – | – |
| Lux et al. ( | ESRD | 24 | – | + | + | – | + |
| Mattioli et al. ( | Stroke | 12 | – | + | + | – | + |
| Meehan et al. ( | Stroke | 18 | – | + | + | – | – |
| Menke et al. ( | Stroke | 8 | – | + | + | – | – |
| Michielsen et al. ( | Stroke | 40 | – | + | + | – | – |
| Milot et al. ( | Stroke | 20 | – | + | + | – | – |
| Pelicioni et al. ( | Stroke | 21 | – | + | + | – | – |
| Pineiro et al. ( | Stroke | 28 | – | + | + | – | – |
| Pinter et al. ( | Stroke | 7 | – | + | – | – | – |
| Ramos-Murguialday et al. ( | Stroke | 32 | – | + | + | – | – |
| Rehme et al. ( | Stroke | 21 | – | + | + | – | – |
| Rijntjes et al. ( | Stroke | 12 | – | + | + | – | – |
| Schaechter et al. ( | Stroke | 7 | – | + | + | – | – |
| Schaechter et al. ( | Stroke | 4 | – | + | + | – | – |
| Shin et al. ( | Stroke | 14 | – | + | + | – | – |
| Sun et al. ( | Stroke | 18 | – | + | + | – | – |
| Szaflarski et al. ( | Stroke | 8 | – | + | + | – | + |
| Takahashi et al. ( | Stroke | 13 | – | + | + | – | – |
| Tombari et al. ( | Stroke | 18 | – | + | + | – | – |
| Veverka et al. ( | Stroke | 14 | – | + | + | – | – |
| Veverka et al. ( | Stroke | 14 | – | + | + | – | – |
| von Lewinski et al. ( | Stroke | 9 | – | + | + | – | – |
| Whitall et al. ( | Stroke | 111 | – | + | + | – | – |
| Zhang et al. ( | ESRD | 46 | – | + | + | – | + |
CKD, chronic kidney disease; ESRD, end-stage renal disease.